Eligible patients save $200 a month on Fareston.

Fareston Is Available and Accessible Through Patient Rx Solutions: A Comprehensive Resource That Makes Getting Fareston Easier

Patient Rx Solutions Can Help You With:

  • Reimbursement assistance: Call 1-800-6-SOLUTIONS (1-800-676-5884) for help from an experienced professional who will work with your insurance company
  • Copay savings of up to $150 per month of therapy (after paying the first $20) if you are eligible* (see below for details)
  • Exploring coverage options (through the Fareston Patient Assistance Program) if you are an eligible uninsured patient or if you are an eligible patient covered under Medicare Part D1
  • Coordinating home delivery of Fareston through specialty pharmacies

Kyowa Kirin, Inc. Is Committed to Making Fareston Affordable Through Copay Assistance*

Contact Patient Rx Solutions today.

You can save up to $150 per month of therapy (after paying the first $20) on your out-of-pocket prescription costs.

It’s Just 3 Easy Steps:

  • Present your Copay Assistance Card along with a valid Fareston prescription to the pharmacist when paying
  • Pay the initial $20 of your copay and any remaining out-of-pocket costs will be reduced by up to $150 per month of therapy
  • Save your Copay Assistance Card for repeated use. In no case will the benefit exceed $150 per 30-day supply

For more information about how you can get easy access to your Fareston prescription, visit www.PatientRxSolutions.com or call 1-800-6-SOLUTIONS (1-800-676-5884).

 

*This offer is not valid for prescriptions under Medicare (including Medicare Advantage, Part A, B and D Plans), Medicaid, VA, DOD, TRICARE, CHAMPUS, or other federal or state healthcare programs. Please see actual copay assistance card for applicable expiration date.
Program managed by PSKW, LLC. on behalf of Kyowa Kirin, Inc. The parties reserve the right to amend or end this program at any time. Product dispensed pursuant to program rules and federal and state laws. Void where prohibited or restricted by law.

Important Safety Information and Boxed Warning

 

Indication

Fareston® (toremifene citrate) 60 mg Tablets is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor-positive or unknown tumors.

WARNING: QT PROLONGATION

Fareston has been shown to prolong the QTc interval in a dose- and concentration-related manner. Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia, or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided.

Contraindications
  • Fareston is contraindicated in patients with known hypersensitivity to the drug, and in patients with congenital/acquired QT prolongation (long QT syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia.
Warnings and Precautions
  • Fareston has been shown to prolong the QT interval. Caution should be exercised in patients with congestive heart failure, hepatic impairment and electrolyte abnormalities. In patients at increased risk, ECGs should be obtained at baseline and as clinically indicated.
  • Hypercalcemia and tumor flare have been reported during the first weeks of treatment with Fareston in some breast cancer patients with bone metastases. If hypercalcemia is severe, Fareston treatment should be discontinued.
  • Patients with preexisting endometrial hyperplasia should not be given long-term Fareston treatment, and patients at high risk for endometrial cancer should be closely monitored.
  • Patients with a history of thromboembolic diseases should not be treated with Fareston.
  • Leukocyte and platelet counts should be monitored when using Fareston in patients with leukopenia and thrombocytopenia.
  • Fareston can cause fetal harm when administered to a pregnant woman.
  • Fareston is only indicated for postmenopausal women. However, premenopausal women prescribed Fareston should use effective nonhormonal contraception and should be apprised of the potential hazard to the fetus should pregnancy occur.
Adverse Reactions
  • The most common adverse reactions are hot flashes, sweating, nausea, and vaginal discharge.
  • To report suspected adverse reactions, contact Kyowa Kirin, Inc. at 1-800-305-FARESTON (1-800-305-3273) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.

Reference: 1. Data on file. Bedminster, NJ: Kyowa Kirin, Inc; 2017.
Expand Safety Information

Important Safety Information and Boxed Warning

Indication

Fareston® (toremifene citrate) 60 mg Tablets is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor-positive or unknown tumors.
WARNING: QT PROLONGATION
Fareston has been shown to prolong the QTc interval in a dose- and concentration-related manner. Prolongation of the QT interval can result in a type of ventricular tachycardia called Torsade de pointes, which may result in syncope, seizure, and/or death. Toremifene should not be prescribed to patients with congenital/acquired QT prolongation, uncorrected hypokalemia, or uncorrected hypomagnesemia. Drugs known to prolong the QT interval and strong CYP3A4 inhibitors should be avoided.
Contraindications
  • Fareston is contraindicated in patients with known hypersensitivity to the drug, and in patients with congenital/acquired QT prolongation (long QT syndrome), uncorrected hypokalemia, or uncorrected hypomagnesemia.
Warnings and Precautions
  • Fareston has been shown to prolong the QT interval. Caution should be exercised in patients with congestive heart failure, hepatic impairment and electrolyte abnormalities. In patients at increased risk, ECGs should be obtained at baseline and as clinically indicated.
  • Hypercalcemia and tumor flare have been reported during the first weeks of treatment with Fareston in some breast cancer patients with bone metastases. If hypercalcemia is severe, Fareston treatment should be discontinued.
  • Patients with preexisting endometrial hyperplasia should not be given long-term Fareston treatment, and patients at high risk for endometrial cancer should be closely monitored.
  • Patients with a history of thromboembolic diseases should not be treated with Fareston.
  • Leukocyte and platelet counts should be monitored when using Fareston in patients with leukopenia and thrombocytopenia.
  • Fareston can cause fetal harm when administered to a pregnant woman.
  • Fareston is only indicated for postmenopausal women. However, premenopausal women prescribed Fareston should use effective nonhormonal contraception and should be apprised of the potential hazard to the fetus should pregnancy occur.
Adverse Reactions
  • The most common adverse reactions are hot flashes, sweating, nausea, and vaginal discharge.
To report suspected adverse reactions, contact Kyowa Kirin, Inc. at 1-800-305-FARESTON (1-800-305-3273) or the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch.